Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Abdom Radiol (NY). 2018 Jan;43(1):218–230. doi: 10.1007/s00261-017-1281-6

Fig. 3. Hepatocellular carcinoma (HCC) treated with drug-eluting bead transarterial chemoembolization (DEB-TACE).

Fig. 3

Biopsy-proven HCC (arrows) in segment 8 showing arterial phase hyperenhancement (A), washout and capsule on portal venous phase (B). After DEB-TACE, no residual enhancement except for a thin rim of enhancement (arrowheads) is seen on arterial (C) and portal venous phases (D) (LR-TR Nonviable).